J. Schwartz

Bioprojet (France) — France

Biochemistry, Genetics and Molecular Biology · Life Sciences

32h-index4.9kcitations131works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Receptor Mechanisms and Signaling(34), Mast cells and histamine(16), Neuroscience and Neuropharmacology Research(13), Neuropeptides and Animal Physiology(13), Neurotransmitter Receptor Influence on Behavior(12)

Publications131 total

Pitolisant 40mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by CPAP
2025
Euclid preparation: I. The Euclid Wide Survey
University of Groningen research database (University of Groningen / Centre for Information Technology)·2021· 8 citedOpen Access
Efficacy of pitolisant in patients with high burden of narcolepsy symptoms: pooled analysis of short-term, placebo-controlled studies
Sleep Medicine·2021· 12 citedOpen Access
Effet à long terme du pitolisant, chez des patients porteurs d’un syndrome d’apnées obstructives du sommeil traités par pression positive continue et présentant une somnolence diurne excessive résiduelle. Étude HAROSA 1
Revue des Maladies Respiratoires Actualités·2021
Pitolisant Evaluation in Patients with OSA and Treated by NCPAP but Still Complaining of Excessive Daytime Sleepiness (EDS) Eudract n°: 2009-017248-14
2020Open Access
Pharmacokinetics of pitolisant in children and adolescents with narcolepsy
Sleep Medicine·2019· 25 citedOpen Access
Evaluation of abuse potential of the narcolepsy medication pitolisant
Sleep Medicine·2019
Pitolisant in combination with other medications for the management of narcolepsy
Sleep Medicine·2019· 1 cited
0623 Long-Term Evaluation of Safety and Efficacy of Pitolisant In Narcolepsy: Harmony III Study
SLEEP·2018· 1 citedOpen Access
0624 Anticataplectic Efficacy of Pitolisant, the First Potent and Highly Selective Histamine H3-Receptor Antagonist/Inverse Agonist
SLEEP·2018Open Access
Anticataplectic efficacy of wakix® (pitolisant), the first potent and highly selective histamine h3-receptor antagonist/inverse agonist in clinics
Sleep Medicine·2017
Pitolisant safety and efficacy in adult narcoleptic patients with or without cataplexy or idiopathic hypersomnia patients in a compassionate use program in france: autorisation temporaire d'utilisation de cohorte (ATUc)
Sleep Medicine·2017
An inverse agonist of the histamine H3 receptor improves wakefulness in narcolepsy: Studies in orexin−/− mice and patients
Neurobiology of Disease·2007· 263 citedOpen Access
<i>N</i>‐methyl‐<scp>d</scp>‐aspartate receptor antagonists enhance histamine neuron activity in rodent brain
Journal of Neurochemistry·2006· 43 cited
CRYSTAL STRUCTURE OF THE EXTRACELLULAR DOMAIN OF MURINE PD-1
2003
Brain-derived neurotrophic factor, dopamine receptors and behavioral sensitization
European Neuropsychopharmacology·2002
Correction of dizocilpine-induced behavioral and biochemical abnormalities by dopamine D3 receptor blockade or invalidation in the mouse
European Neuropsychopharmacology·2002
The Dopamine D3 Receptor and Its Implication in Neuropsychiatry Disorders and Their Treatments
Handbook of experimental pharmacology·2002· 5 cited
6 The Histamine H3 Receptor and its Ligands
Progress in medicinal chemistry·2001· 47 cited
Anti-Inflammatory and Antinociceptive Properties of BP 2-94, a Histamine H3-Receptor Agonist Prodrug
Journal of Pharmacology and Experimental Therapeutics·2000· 40 cited
page 1 of 7Next →

Frequent Co-authors

Pierre Sokoloff(8), J Velly(7), Marie‐Pascale Martres(6), Pascal Bousquet(5), Claude P. Gros(5), Jeanne‐Marie Lecomte(5), M. Garbarg(5), B. Rouot(5), H. Pollard(4), Jorge Díaz(3), James A. Feldman(3), L. Lannfelt(3), Erik G. Jönsson(3), Nathalie Griffon(3), Catherine Llorens‐Cortés(3), G. LECLERC(3), G. Barbin(3), Holger Stark(3), Jean‐Michel Arrang(3), Walter Schunack(3)